A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia
A Phase 4, Randomized, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia
Sponsor: Cumberland Pharmaceuticals
This PHASE4 trial investigates Euvolemia and Hypervolemia and is currently completed. Cumberland Pharmaceuticals leads this study, which shows 10 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cumberland Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Afula, Israel , Ashkelon, Israel , Bangalore, India , Bhopal, India , Charleston, United States , Haifa, Israel , Holon, Israel , Hyderabaad, India , Jerusalem, Israel , Karnāl, India and 5 more locations